Endotypes of Severe Asthma: 5 Questions on Pathways, Biomarkers, Biologics

Key factors in choosing appropriate biologic therapy for a patient with severe asthma include consideration of the specific mechanistic pathway that underlies the presentation, investigation of biomarker levels, and evaluation of comorbid inflammatory disease.

Following are 5 questions on these topics that are based on a comprehensive review and international expert opinion published in the Journal of Allergy and Clinical Immunology: In Practice by a group of clinicians recognized internationally for knowledge of severe asthma and of biologic medications. Test your endotype IQ.